Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Grid Therapeutics logo — company profile

Grid Therapeutics

Founded 2014 United States Durham, United States 4 employees Series B Total: $5.00M Biotechnology, Life Sciences +1

General Information

Company Name Grid Therapeutics
Founded Year 2014
Location United States Durham, United States
Founders / Decision Makers
Team member
Employees 4
Industries Biotechnology, Life Sciences, Medical Devices
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Grid Therapeutics. To contact Grid Therapeutics, visit gridtherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Grid Therapeutics compare?

A PDF of Grid Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Grid Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Grid Therapeutics

Grid Therapeutics is a biotech company based in Durham, North Carolina, founded in 2014. The company is built on innovative science developed by Edward F. Patz, Jr. MD and a team of scientists at Duke University Medical Center. Grid Therapeutics is focused on developing the first human-derived targeted immunotherapy for cancer. Their lead asset, "GT103," is currently enrolling the first-in-man Phase 1 clinical trial in refractory NSCLC patients. The antibody, isolated from patient's B-cells using state-of-the-art molecular genomic techniques, was discovered in exceptional outcome early-stage lung cancer patients who did not develop metastasis. Grid's approach holds promise in the field of targeted immunotherapy, offering potential breakthroughs in cancer treatment.

Business keywords: Biotech, Immunotherapy, Cancer, Targeted therapy, Drug development, Clinical trials, Lung cancer, B-cell, Molecular genomic techniques, Phase 1, Medical research, Innovative science, Duke University Medical Center, Patient-centered therapy

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $5.00M 3
Jeffery “TJ” Heyman, Milestone Holdings +1
27 Mar 2018
Series A Undisclosed 1
Longview International
14 Sep 2017

Grid Therapeutics Alternatives & Competitors

View All Alternatives
Grid Therapeutics vs
OSE Immunotherapeutics
OSE Immunotherapeutics France

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients

Grant
76 employees
Biotechnology, Medical Devices
Grid Therapeutics vs
SCG Cell Therapy
SCG Cell Therapy Singapore

Leading the Next Wave of Biotech Breakthroughs

Series C
24 employees
Biotechnology, Life Sciences
Grid Therapeutics vs
Alligator Bioscience
Alligator Bioscience

Pioneering advancements in immunotherapy with innovative drug candidates and proprietary technology...

Venture round
11-50 employees
Biotechnology, Health Care
View all alternatives

FAQ About Grid Therapeutics

Grid Therapeutics is a biotech company based on the innovative science first developed by Edward F. Patz, Jr. MD and his team of scientists at Duke University Medical Center. Located in Durham, North Carolina, Grid is developing the first human derived targeted immunotherapy for cancer. The antibody...
Grid Therapeutics was founded in 2014.
Grid Therapeutics is headquartered in Durham, United States.
Grid Therapeutics operates in Biotechnology, Life Sciences and Medical Devices. Its work centres on Biotech, Immunotherapy, Cancer and Targeted therapy.
Grid Therapeutics has approximately 4 employees.
Grid Therapeutics has completed 2 funding rounds, raising a total of $5.00M. The latest funding stage is Series B.
Top alternatives and competitors to Grid Therapeutics include OSE Immunotherapeutics, SCG Cell Therapy, Alligator Bioscience, Seneca Therapeutics, Inc., Enterome. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Grid Therapeutics and OSE Immunotherapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Grid Therapeutics, https://bouncewatch.com/company/grid-therapeutics, updated 27 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes